STUGERON® TABLETS COMPOSITION: Cinnarizine 25 mg per tablet. PHARMACOLOGICAL CLASSIFICATION: A. 5.7 Antihistaminics, anti-emetics and antivertigo preparations. PHARMACOLOGICAL ACTION: Pharmacodynamics Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking calcium channels. Cinnarizine increases erythrocyte deformability and decreases blood viscosity in vitro. Cinnarizine inhibits stimulation of the vestibular system. Pharmacokinetics The peak plasma levels of cinnarizine are obtained 1 to 3 hours after intake. Cinnarizine disappears from plasma with a half-life of 4 hours. Cinnarizine is completely metabolised. About 1/3 of these metabolites are eliminated in the urine and 2/3 in the faeces. The plasma protein binding of cinnarizine is 91%. INDICATIONS: Control of vestibular symptoms of both peripheral and central origin and of labyrinthine disorders including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting. Prophylaxis of motion sickness. Adjunct therapy for symptoms of peripheral arterial disease. CONTRA-INDICATIONS: In patients with known hypersensitivity to cinnarizine. The safety of STUGERON tablets in pregnant and lactating women has not been established. Parkinson's disease.
There are no additional images for this product.